Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

ASLAN Reports Positive Phase I Results from Cancer Drug

publication date: Mar 16, 2015
ASLAN Pharma of Singapore announced that its second in-licensed cancer drug, ASLAN002, was safe and well-tolerated in its initial Phase I trial. ASLAN002 is a small-molecule dual inhibitor of the cMET receptor tyrosine kinase and RON immune checkpoint that ASLAN in-licensed from Bristol-Myers Squibb. In addition, the company said ASLAN002 resulted in long-term stable disease and partial responses in specific tumor types. ASLAN plans to advance ASLAN002 into a Phase II trial in "highly selected" patients with gastric cancer in Asia Pacific centers. More details....

Stock Symbol: (NYSE: BMY)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here